| Dr Michael Carvajal, PSYD | |
|
915 Vassar Dr Ne Ste 170, Albuquerque, NM 87106-2727 | |
| (505) 272-8833 | |
| (505) 272-8316 |
| Full Name | Dr Michael Carvajal |
|---|---|
| Gender | Male |
| Speciality | Clinical Psychologist |
| Experience | 9 Years |
| Location | 915 Vassar Dr Ne Ste 170, Albuquerque, New Mexico |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1003337767 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 103TC0700X | Psychologist - Clinical | PSY1474 (New Mexico) | Secondary |
| 103G00000X | Clinical Neuropsychologist | PSY1474 (New Mexico) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Unm Hospital | 7618889528 | 229 |
News Archive
The Associated Press/Chicago Tribune reports on interest group activity in Iowa. The AARP recently "announced it is launching an advertising and organizing blitz designed to 'debunk the myths' being offered by health care reform critics. 'We won't stand idle when opponents of health care reform attempt to scare or mislead the American people - and older Americans in particular - about what fixing the system really means,' said Bruce Koeppl, AARP Iowa director."
GlaxoSmithKline has announced that the U.S. Food and Drug Administration (FDA) has approved Twinrix [Hepatitis A Vaccine (Inactivated) and Hepatitis B (Recombinant) Vaccine], for an accelerated dosing schedule that consists of three doses given within three weeks followed by a booster dose at 12 months.
Traslational Cancer Drugs Pharma, S.L. ("TCD") announced today that the first patient was treated on Friday the 18th of February with TCD-717 in a Phase I study performed in patients with advanced solid tumors. TCD-717 is a first-in-class, small molecule that precisely inhibits Choline Kinase Alpha, an enzyme heavily involved in the carcinogenic process. A total of 30 patients are planned to be treated in the trial, which will be conducted in accordance with FDA approval, in two leading medical centers in the U.S. The
DelMar Pharmaceuticals, Inc., a biopharmaceutical company focused on developing and commercializing proven cancer therapies in new orphan drug indications, today announced the closing of a registered direct placement (Placement) with $2.6 million received from the offering.
› Verified 9 days ago
| Entity Name | Unm Hospital |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1689747552 PECOS PAC ID: 7618889528 Enrollment ID: O20040110000011 |
News Archive
The Associated Press/Chicago Tribune reports on interest group activity in Iowa. The AARP recently "announced it is launching an advertising and organizing blitz designed to 'debunk the myths' being offered by health care reform critics. 'We won't stand idle when opponents of health care reform attempt to scare or mislead the American people - and older Americans in particular - about what fixing the system really means,' said Bruce Koeppl, AARP Iowa director."
GlaxoSmithKline has announced that the U.S. Food and Drug Administration (FDA) has approved Twinrix [Hepatitis A Vaccine (Inactivated) and Hepatitis B (Recombinant) Vaccine], for an accelerated dosing schedule that consists of three doses given within three weeks followed by a booster dose at 12 months.
Traslational Cancer Drugs Pharma, S.L. ("TCD") announced today that the first patient was treated on Friday the 18th of February with TCD-717 in a Phase I study performed in patients with advanced solid tumors. TCD-717 is a first-in-class, small molecule that precisely inhibits Choline Kinase Alpha, an enzyme heavily involved in the carcinogenic process. A total of 30 patients are planned to be treated in the trial, which will be conducted in accordance with FDA approval, in two leading medical centers in the U.S. The
DelMar Pharmaceuticals, Inc., a biopharmaceutical company focused on developing and commercializing proven cancer therapies in new orphan drug indications, today announced the closing of a registered direct placement (Placement) with $2.6 million received from the offering.
› Verified 9 days ago
| Entity Name | Unm Medical Group Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1831218627 PECOS PAC ID: 4981795267 Enrollment ID: O20070801000589 |
News Archive
The Associated Press/Chicago Tribune reports on interest group activity in Iowa. The AARP recently "announced it is launching an advertising and organizing blitz designed to 'debunk the myths' being offered by health care reform critics. 'We won't stand idle when opponents of health care reform attempt to scare or mislead the American people - and older Americans in particular - about what fixing the system really means,' said Bruce Koeppl, AARP Iowa director."
GlaxoSmithKline has announced that the U.S. Food and Drug Administration (FDA) has approved Twinrix [Hepatitis A Vaccine (Inactivated) and Hepatitis B (Recombinant) Vaccine], for an accelerated dosing schedule that consists of three doses given within three weeks followed by a booster dose at 12 months.
Traslational Cancer Drugs Pharma, S.L. ("TCD") announced today that the first patient was treated on Friday the 18th of February with TCD-717 in a Phase I study performed in patients with advanced solid tumors. TCD-717 is a first-in-class, small molecule that precisely inhibits Choline Kinase Alpha, an enzyme heavily involved in the carcinogenic process. A total of 30 patients are planned to be treated in the trial, which will be conducted in accordance with FDA approval, in two leading medical centers in the U.S. The
DelMar Pharmaceuticals, Inc., a biopharmaceutical company focused on developing and commercializing proven cancer therapies in new orphan drug indications, today announced the closing of a registered direct placement (Placement) with $2.6 million received from the offering.
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Michael Carvajal, PSYD 933 Bradbury Dr Se Ste 2222, Albuquerque, NM 87106-4375 Ph: (505) 272-3120 | Dr Michael Carvajal, PSYD 915 Vassar Dr Ne Ste 170, Albuquerque, NM 87106-2727 Ph: (505) 272-8833 |
News Archive
The Associated Press/Chicago Tribune reports on interest group activity in Iowa. The AARP recently "announced it is launching an advertising and organizing blitz designed to 'debunk the myths' being offered by health care reform critics. 'We won't stand idle when opponents of health care reform attempt to scare or mislead the American people - and older Americans in particular - about what fixing the system really means,' said Bruce Koeppl, AARP Iowa director."
GlaxoSmithKline has announced that the U.S. Food and Drug Administration (FDA) has approved Twinrix [Hepatitis A Vaccine (Inactivated) and Hepatitis B (Recombinant) Vaccine], for an accelerated dosing schedule that consists of three doses given within three weeks followed by a booster dose at 12 months.
Traslational Cancer Drugs Pharma, S.L. ("TCD") announced today that the first patient was treated on Friday the 18th of February with TCD-717 in a Phase I study performed in patients with advanced solid tumors. TCD-717 is a first-in-class, small molecule that precisely inhibits Choline Kinase Alpha, an enzyme heavily involved in the carcinogenic process. A total of 30 patients are planned to be treated in the trial, which will be conducted in accordance with FDA approval, in two leading medical centers in the U.S. The
DelMar Pharmaceuticals, Inc., a biopharmaceutical company focused on developing and commercializing proven cancer therapies in new orphan drug indications, today announced the closing of a registered direct placement (Placement) with $2.6 million received from the offering.
› Verified 9 days ago